These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33705411)

  • 1. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
    Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN
    PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
    Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
    J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
    Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
    J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy against
    Baldwin SL; Reese VA; Larsen SE; Pecor T; Brown BP; Granger B; Podell BK; Fox CB; Reed SG; Coler RN
    Front Microbiol; 2022; 13():935444. PubMed ID: 36090093
    [No Abstract]   [Full Text] [Related]  

  • 5. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.
    Baldwin SL; Ching LK; Pine SO; Moutaftsi M; Lucas E; Vallur A; Orr MT; Bertholet S; Reed SG; Coler RN
    J Immunol; 2013 Sep; 191(5):2514-2525. PubMed ID: 23904160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.
    Orr MT; Beebe EA; Hudson TE; Moon JJ; Fox CB; Reed SG; Coler RN
    PLoS One; 2014; 9(1):e83884. PubMed ID: 24404140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Cho SN; Coler RN; Reed SG; Shin SJ
    Vaccine; 2016 Apr; 34(19):2179-87. PubMed ID: 27005808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.
    Orr MT; Beebe EA; Hudson TE; Argilla D; Huang PW; Reese VA; Fox CB; Reed SG; Coler RN
    Vaccine; 2015 Nov; 33(48):6570-8. PubMed ID: 26541135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
    Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ
    Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.
    Duthie MS; Coler RN; Laurance JD; Sampaio LH; Oliveira RM; Sousa AL; Stefani MM; Maeda Y; Matsuoka M; Makino M; Reed SG
    Infect Immun; 2014 Sep; 82(9):3979-85. PubMed ID: 25024362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
    Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
    PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.
    Orr MT; Duthie MS; Windish HP; Lucas EA; Guderian JA; Hudson TE; Shaverdian N; O'Donnell J; Desbien AL; Reed SG; Coler RN
    Eur J Immunol; 2013 Sep; 43(9):2398-408. PubMed ID: 23716300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model.
    Rao M; Cadieux N; Fitzpatrick M; Reed S; Arsenian S; Valentini D; Parida S; Dodoo E; Zumla A; Maeurer M
    Int J Infect Dis; 2017 Mar; 56():274-282. PubMed ID: 28161464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.
    Baldwin SL; Reese VA; Huang PW; Beebe EA; Podell BK; Reed SG; Coler RN
    Clin Vaccine Immunol; 2016 Feb; 23(2):137-47. PubMed ID: 26656121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.
    Windish HP; Duthie MS; Misquith A; Ireton G; Lucas E; Laurance JD; Bailor RH; Coler RN; Reed SG
    Vaccine; 2011 Oct; 29(44):7842-8. PubMed ID: 21816196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines.
    Grover A; Troudt J; Foster C; Basaraba R; Izzo A
    Immunology; 2014 May; 142(1):111-23. PubMed ID: 24350616
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Jia Q; Masleša-Galić S; Nava S; Horwitz MA
    mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.